Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: A case report

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 6, 2010, Pages 469-481

  Chen, Ying Chou ^a   Wang, Pei Wen ^b   Pan, Tai Long ^b   Bazylak, Grzegorz ^c   Shen, Jiann Jong ^b,d  

^a Kaohsiung Medical Center   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Autoimmune diseases; Biologic therapies; Fusion proteins; Mass spectrometry; Peptide mass fingerprinting; Proteomics

Indexed keywords

ANTITHROMBIN; APOLIPOPROTEIN; BIOLOGICAL MARKER; ETANERCEPT; GAMMA INTERFERON; GROWTH FACTOR; HAPTOGLOBIN; IMMUNOGLOBULIN A; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMA PROTEIN; VITAMIN D BINDING PROTEIN;

ARTICLE; BIOLOGICAL THERAPY; CASE REPORT; CHILD; DOWN REGULATION; DRUG SCREENING; ENTHESITIS RELATED ARTHRITIS; FEMALE; HUMAN; IMMUNE RESPONSE; JUVENILE RHEUMATOID ARTHRITIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; TAIWAN; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOGLOBULIN G; MALE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROTEOMICS; RECEPTORS, TUMOR NECROSIS FACTOR; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77955727413     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710791515987     Document Type: Article

References (81)

1. Ravelli, A.; Martini, A. Juvenile idiopathic arthritis. Lancet, 2007, 369, 767-778.
2. Huang, J. L.; Yeh, C. C.; Shaw, C. K.; Yao, T. C.; Chen, L. C.; Lee, T. D.; Kuo, M. L. HLA-DRB1 genotyping in patients with juvenile idiopathic arthritis in Taiwan. Eur. J. Immunigen., 2004, 31, 185-188.
3. Petty, R. E.; Southwood, T. R.; Manners, P.; Bum, J.; Glass, D. N.; Goldenberg, J.; He, X.; Maldonado-Cocco, J.; Orozco-Alcala, J.; Prieur, A. M.; Suarez-Almazor, M. E.; Woo, P. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol., 2004, 31, 390-392.
4. Prahalad, S.; Glass, D. N. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatric Rheum., 2008, 6, 11-26.
5. Phelan, J. D.; Thompson, S. D.; Glass, D. N. Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits. Genes Immun., 2006, 7, 1-10.
6. Borchers, A. T.; Selmi. C.; Cheema. G.; Keen, C. L.; Shoenfeld, Y.; Gershwin, M. E. Juvenile idiopathic arthritis. Autoimmun. Rev., 2006, 5, 279-298.
7. Saxena, N.; Misra, R.; Aggarwal, A. Is the enthesitis-related arthritis subtype of juvenile idiopathic arthritis a form of chronic reactive arthritis? Rheumatology, 2006, 45, 1129-1132.
8. Pollanen, R.; Sillat, T.; Pajarinen, J.; Levon, J.; Kaivosoja, E.; Konttinen, Y. T. Microbial antigens mediate HLA-B27 diseases via TLRs. J. Autoimmun., 2009, 32, 172-177.
9. Tse, S. M. L.; Burgos-Vargas, R.; Laxer, R. M. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthropathy. Arthritis Rheum., 2005, 52, 2103-2108.
10. Braun, J.; Bollow, M.; Remlinger, G.; Eggens, U.; Rudwaleit, M.; Distler, A.; Sieper, J. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum., 1998, 41, 58-67.
11. Sulpice, M.; Deslandre, C. J.; Quartier, P. Efficiacy and safety of TNFα antagonist theraphy in patients with juvenile spondyloarthropathies. Joint Bone Spine, 2009, 76, 24-27.
12. Murray, K. J.; Lovell. D. J. Advanced therapy for juvenile arthritis. Best Pract. Res. Clin. Rheumatol, 2002, 16, 361-378.
13. Fogler, W. E. Treating rheumatoid arthritis with DMARDs and biologics. Drug Discov. World, 2008, 9, 15-20.
14. Hashkes, P. J.; Laxer, R. M. Medical treatment of Juvenile Idiopathic Arthritis. JAMA, 2005, 294, 1671-1684.
15. Haines, K. A. Juvenile idiopathic arthritis: therapies in the 21st century. Bull. NYU Hosp. Int. Dis., 2007, 65, 205-211.
16. Hayward, K.; Wallace, C. A. Recent developments in antirheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res. Ther., 2009, 11, 216.
17. Ruperto, N.; Lovell, D. J.; Quartier, P.; Paz, E.; Rubio-Perez, N.; Silva, C. A.; Abud-Mendoza, C.; Burgos-Vargas, R.; Gerloni, V.; Melo-Gomes, J. A.; Saad-Magalhaes, C.; Sztajnbok, F.; Goldenstein-Schainberg, C.; Scheinberg, M.; Penades, I. C.; Fischbach, M.; Orozco, J.; Hashkes, P. J.; Hom, C.; Jung, L.; Lepore, L.; Oliveira, S.; Wallace, C. A.; Sigal, L. H.; Block, A. J.; Covucci, A.; Martini, A.; Giannini, E. H. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled withdrawal trial. Lancet, 2008, 372, 383-391.
18. Lovell, D. J.; Giannini, E. H.; Reiff, A.; Cawkwell, G. D.; Silverman, E. D.; Nocton, J. J.; Stein, L. D.; Gedalia. A.; Ilowite, N. T.; Wallace, C. A.; Whitmore, J.; Finck, B. K. Etanercept in children with polyarticular juvenile rheumatoid arthritis pediatric rheumatology collaborative study group. N. Engl. J. Med., 2000, 342, 763-769.
19. Prince, F. H.; Geerdink, L. M.; Borsboom, G. J.; Twilt, M.; Van Rossum, M. A.; Hopppenreijs, E. P.; Cate, R. T.; Koopman-Keemink, Y.; van Santen-Hoeufft, M.; Raat, H.; van Suijlekom-Smit, L. W. Major improvements in health-related quality of life during the use of ethanercept in patients with previously refractory juvenile idiophatic arthritis. Ann. Rheum. Dis., 2009, 69, 138-142.
20. Prince, F. H. M.; Twilt, M.; Simon, S. C. M.; van Rossum, M. A. J.; Armbrust, W.; Hoppenreijs, E. P. A. H.; Kamphuis, S.; van Santen-Hoeufft, M.; Koopman-Keemink, Y.; Wulffraat, N. M.; ten Cate, R.; van Sijlekom-Smit, L. W. A. When and how to stop etanercept after successful treatment of patients with juvenile idiophatic arthritis. Ann. Rheum. Dis., 2009, 68, 1228-1229.
21. Yim, D. S.; Zhou, H.; Buckwalter, M.; Nestorov, I.; Peck, C. C.; Lee, H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J. Clin. Pharmacol, 2005, 45, 246-256.
22. Pain, C. E.; McCann, L. J. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics, 2009, 3, 127-139.
23. Tse, S. M.; Laxer, R. M.; Babyn, P. S.; Doria, A. S. Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept. J. Rheumatol, 2006, 33, 1186-1188.
24. Kutukculer, N.; Caglayan, S.; Aydogdu, F. Study of proinflammatory (TNF-α, IL-1α, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol, 1998, 17, 288-292.
25. Ducharme, E.; Weinberg, J. M. Etanercept. Exp. Opin. Biol. Ther., 2008, 8, 491-502.
26. Fabre, S.; Dupuy, A. M.; Dossat, N.; Guisset, C.; Cohen, J. D.; Cristol, J. P.; Daures, J. P.; Jorgensen, C. Protein biochip technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin. Exp. Immunol, 2008, 153, 188-195.
27. Fouache, D.; Goeb, V.; Massy-Guillemant, N.; Avenel, G.; Bacquet-Deschryver, H.; Kozyreff-Meurice, M.; Menard, J. F.; Muraine, M.; Savoye, G.; Le Loet, X.; Tharasse, C.; Vittecoq, O. Paradoxical adverse events of anti-tumor necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology, 2009, 48, 761-764.
28. Braun, J.; Brandt, J.; Listing, J.; Rudwaleit, M.; Sieper, J. Biologic therapies in the spondylarthritis: new opportunities, new challenges. Curr. Opin. Rheumatol, 2003, 15, 394-407.
29. Pavy, S.; Allanore, Y.; Kahan, A. Spondylarthropathies and anti-TNFa drugs. Rev. Med. Interne., 2005, 26, 717-724.
30. Lovell, D. J.; Reiff, A.; Jones, O. Y.; Schneider, R.; Nocton, J.; Stein, L. D.; Gedalia, A.; Ilowite, N. T.; Wallace, C. A.; Whitmore, J. B.; White, B.; Giannini, E. H. Pediatric rheumatology collaborative study group long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum., 2006, 54, 1987-1994.
31. Luster, A. D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 1998, 338, 436-445.
32. Choy, E. H.; Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344, 907-916.
33. Yilmaz, M.; Kendirli, S. G.; Altintas, D.; Bingol, G.; Antmen, B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin. Rheumatol, 2001, 20, 30-35.
34. Ozen, S.; Saatci, U.; Bakkaloglu, A.; Ozdemir, O.; Besbas, N.; Kirazli, S.; Ozdemir, S. Interleukin-1,-6, and-8 levels in juvenile chronic arthritis. Clin. Rheumatol, 1997, 16, 173-178.
35. Wang, P. W.; Pan, T. L.; Lin, C. H.; Shen, J. J.; Chen, Y. R. Characterization of plasma protein profiles from patients with neurofibromatosis. Clin. Chim. Acta, 2007, 380, 139-144.
36. Zlacka, D.; Vavrincova, P.; Hien-Nguyen, T. T.; Hromadnikova, I. Frequency of anti-hsp60,-65 and-70 antibodies in sera of patients with juvenile idiopathic arthritis. J. Autoimmun., 2006, 27, 81-88.
37. Massa, M.; Passalia, M.; Manzoni, S. M.; Campanelli, R.; Ciardelli, L.; Yung, G. P.; Kamphuis, S.; Pistorio, A.; Meli, V.; Sette, A.; Prakken, B.; Martini, A.; Albani, S. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum., 2007, 56, 1648-1657.
38. Toh, M. L.; Marotte, H.; Blond, J. L.; Jhumka, U.; Eljaafari, A.; Mougin, B.; Miossec, P. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum., 2006, 54, 2109-2118.
39. Tampoia, M.; Brescia, V.; Fontana, A.; Maggiolini, P.; Zucano, A.; Pansini, N. Proteomics: New advances in diagnosis of rheumatoid arthritis. Clin. Chim. Acta, 2005, 357, 219-225.
40. Gibson, D. S.; Rooney, M. E. The human synovial fluid proteome: A key factor in the pathology of joint disease. Proteomics Clin. Appl, 2007, 1, 889-899.
41. Tilleman, K.; Deforce, D. Proteomics in rheumatology. Exp. Rev. Proteomics, 2008, 5, 755-759.
42. Wilson, R.; Bateman, J. F. Cartilage proteomics: Challenges, solutions and recent advances. Proteomics Clin. Appl, 2008, 2, 251-263.
43. Camafeita, E.; Lamas, J. R.; Calvo, E.; Lopez, J. A.; Fernandez-Gutierrez, B. Proteomics: New insights into rheumatic diseases. Proteomics Clin. Appl, 2009, 3, 226-241.
44. Gibson, D. S.; Blelock, S.; Brockbank, S.; Curry, J.; Healy, A.; McAllister, C.; Rooney, M. E. Proteomic analysis of recurrent joint inflammation in juvenile idiophatic arthritis. J. Proteome. Res., 2006, 5, 1988-1995.
45. Gibson, D. S.; Blelock, S.; Curry, J.; Finnegan, S.; Healy, A.; Scaife, C.; McAllister, C.; Pennington, S.; Dunn, M.; Rooney, M. Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis - Proteomic patterns of joint inflammation in early stage disease. J. Proteomics, 2009, 72, 656-676.
46. Miyamae, T.; Malehom, D. E.; Lemster, B.; Mori, M.; Imagawa, T.; Yokota, S.; Bigbee, W. L.; Welsh, M.; Klarskov, K.; Nishomoto, N.; Vallejo, A. N.; Hirsch, R. Serum protein profile in systemiconset juvenile idiophatic arthritis differentiates response versus nonresponse to theraphy. Arthritis Res. Ther., 2005, 7, R746-R755.
47. Low, J. M.; Chauhan, A. K.; Gibson, D. S.; Zhu, M.; Chen, S.; Rooney, M. E.; Ombrello, M. J.; Moore, T. L. Proteomic analysis of circulating immune complexes in juvenile idiophatic arthritis reveals disease-associated proteins. Proteomics Clin Appl., 2009, 3, 829-840.
48. Tilleman, K.; van Beneden, K.; Dhondt, A.; Hoffman, I.; De Keyser, F.; Veys, E.; Elewaut, D.; Deforce, D. Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics, 2005, 5, 2247-2257.
49. Liu, W.; Li, X.; Ding, F.; Li, Y. Using SELDI-TOF MS to identify serum biomarkers of rheumatoid arthritis. Scand. J. Rheumatol., 2008, 37, 94-102.
50. Liu, J.; Zhu, P.; Peng, J.; Li, K.; Du, J.; Gu, J.; Ou, Y. Identification of disease-associated proteins by proteomic approach in ankylosing spondylitis. Biochem. Biophys. Res. Commun., 2007, 357, 531-536.
51. Tynjala, P.; Lahdenne, P.; Vahasalo, P.; Kautiainen, H.; Honkanen, V. Impact of anti-TNF treatment on growth in severe juvenile idiophatic arthritis. Ann. Rheum. Dis., 2006, 65, 1044-1049.
52. Special Report: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis, Decision Resources 12 June 2009, Pub ID: DECR2287666, pp. 25, http://www.marketresearch.com, (accessed at 12.07. 2009).
53. Flato, B.; Aasland, A.; Vinje, O.; Forre, O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J. Rheumatol., 1998, 25, 366-375.
54. ® Human Cytokine Antibody Array Protocol, pp. 6-16. http://www.raybiotech.com, (accessed at 15.09. 2008).
55. Chen, Y. C.; Wang, P. W.; Pan, T. L.; Wallace, C. G.; Chen, C. J. Proteomic analysis of Down's syndrome patients with gout. Clin. Chim. Acta, 2006, 369, 89-94.
56. Pan, T. L.; Wang, P. W.; Huang, C. C.; Goto, S.; Chen, C. L. Expression by functional proteomics of spontaneous tolerance in rat orthotopic liver transplantation. Immunology, 2004, 113, 57-64.
57. Wallace, C. A.; Ruperto, N.; Giannini, E. Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group: Preliminary criteria for clinical remission for select categories of juvenile idiophatic arthritis. J. Rheumatol., 2004, 31, 2290-2294.
58. Seipp, M. T.; Erali, M.; Wies, R. L.; Wittwer, C. HLA-B27 typing: Evaluation of an allele-specific PCR melting assay and two flow cytometric antigen assays. Cytometry B, 2005, 63 B, 10-15.
59. Sonkar, G. K.; Usha-Singh, S. Is HLA-B27 a useful test in the diagnosis of juvenile spondyloarthropathies? Singapore Med. J., 2008, 49, 795-799.
60. Bansard, C.; Lequerre, T.; Daveau, M.; Boyer, O.; Tron, F.; Salier, J. P.; Vittecoq, O.; Le-Loet, X. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? Rheumatology, 2009, 48, 1021-1028.
61. Hueber, W.; Tomooka, B. H.; Zhao, X.; Kidd, B. A.; Drijfhout, J. W.; Fries, J. F.; van Venrooij, W. J.; Metzger, A. L.; Genovese, M. C.; Robinson, W. H. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis., 2007, 66, 712-719.
62. McCann, L. J.; Woo, P. Biologic therapies in juvenile idiopathic arthritis: why and for whom? Acta Rheumatol. Port., 2007, 32, 15-26.
63. Al-Shukaili, A. K.; Al-Jabri, A. A. Rheumatoid arthritis cytokines and hypoxia. What is the link? Saudi Med. J., 2006, 27, 1642-1649.
64. De Benedetti, F.; Pignatti, P.; Biffi, M.; Bono, E.; Wahid, S.; Ingegnoli, F.; Chang, S. Y.; Alexander, H.; Massa, M.; Pistorio, A.; Martini, A.; Pitzalis, C.; Sinigaglia, F.; Rogge, L. Increased expression of alpha (13)-fucosyltransferase-VII and P-selectin binding of synovial fluid T cells in juvenile idiopathic arthritis. J. Rheumatol., 2003, 30, 1611-1615.
65. Kanakoudi-Tsakalidou, F.; Tzimouli, V.; Pratsidou-Gertsi, P.; Chronopoulou, E.; Trachana, M. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine, 2008, 42, 293-297.
66. Jarvis, J. N.; Jiang, K.; Petty, H. R.; Centola, M. Neutrophils: the forgotten cell in JIA disease pathogenesis. Pediatr. Rheumatol. Online J., 2007, 5, 13.
67. de Jager, W.; Hoppenreijs, E. P.; Wulffraat, N. M.; Wedderburn, L. R.; Kuis, W.; Prakken, B. J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a crosssectional study. Ann. Rheum. Dis., 2007, 66, 589-598.
68. Havemose-Poulsen, A.; Sorensen, L. K.; Stoltze, K.; Bendtzen, K.; Holmstrup, P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis juvenile idiopathic arthritis and rheumatoid arthritis. J. Periodontol., 2005, 76, 2276-2285.
69. Walzog, B.; Weinmann, P.; Jeblonski, F.; Scharffetter-Kochanek, K.; Bommert, K.; Gaehtgens, P. A role for beta (2) integrins (CD11/CD18) in the regulation of cytokine gene expression of polymorphonuclear neutrophils during the inflammatory response. FASEB J., 1999, 13, 1855-1865.
70. Clavel, C.; Nogueira, L.; Laurent, L.; Iobagiu, C.; Vincent, C.; Sebbag, M.; Serre, G. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum., 2008, 58, 678-688.
71. Arredouani, M. S.; Kasran, A.; Vanoirbeek, J. A.; Berger, F. G.; Baumann, H.; Ceuppens, J. L. Haptoglobin dampens endotoxininduced inflammatory effects both in vitro and in vivo. Immunology, 2005, 114, 263-271.
72. Fall, N.; Barnes, M.; Thornton, S.; Luyrink, L.; Olson, J.; Ilowite, N. T.; Gottlieb, B. S.; Griffin, T.; Sherry, D. D.; Thompson, S.; Glass, D. N.; Colbert, R. A.; Grom, A. A. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum., 2007, 56, 3793-3804.
73. Dwivedi, R. C.; Dhindsa, N.; Krokhin, O. V.; Cortens, J.; Wilkins, J. A.; El-Gabalawy, H. S. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res. Ther., 2009, 11, R32.
74. Thornton, J.; Ashcroft, D.; O'Neill, T.; Elliott, R.; Adams, J.; Roberts, C.; Rooney, M.; Symmons, D. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol. Assess., 2008, 12, 1-208.
75. Burnham, J. M.; Shults, J.; Weinstein, R.; Lewis, J. D.; Leonard, M. B. Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann. Rheum. Dis., 2006, 65, 1074-1079.
76. Ginaldi, L.; Di Benedetto, M. C.; De Martinis, M. Osteoporosis inflammation and ageing. Immun. Ageing, 2005, 2, 14.
77. López-Farre, A. J.; Mateos-Caceres, P. J.; Sacristan, D.; Azcona, L.; Bernardo, E.; de Prada, T. P.; Alonso-Orgaz, S.; Fernández-Arquero, M.; Fernández-Ortiz, A.; Macaya, C. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J. Proteome Res., 2007, 6, 2481-2487.
78. Hyka, N.; Dayer, J. M.; Modoux, C.; Kohno, T.; Edwards, C. K. 3rd; Roux-Lombard, P.; Burger, D. Aolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood, 2001, 97, 2381-2389.
79. Sattar, N.; Crompton, P.; Cherry, L.; Kane, D.; Lowe, G.; McInnes, I. B. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind placebo-controlled study. Arthritis Rheum., 2007, 56, 831-839.
80. Verma, A.; List, A. F. Cytokine targets in the treatment of myelodysplastic syndromes. Curr. Hematol. Rep., 2005, 4, 429-435.
81. Stone, J. H.; Rajapakse, V. N.; Hoffman, G. S.; Specks, U.; Merkel, P. A.; Spiera, R. F.; Davis, J. C.; Clair, E. W. St.; McCune, J.; Ross, S.; Hitt, B. A.; Veenstra, T. D.; Conrads, T. P.; Liotta, L. A.; Petricoin III, E. P. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum., 2005, 52, 902-910.